Vuno invests $2M, sells lung AI in Japan to rival
Vuno has invested in and sold its lung disease diagnosis AI technology in Japan to its rival Korean company Coreline Soft.
The two companies recently entered into a strategic partnership to jointly raise their competitiveness in the growing global medical imaging AI segment.
Vuno invested 3.4 billion won ($2.3 million) in Coreline Soft, to which it sold and transferred the rights of its AI-powered lung disease diagnosis support software – its first offering in Japan. This then marks Coreline Soft’s entry into the Japanese market, which is noted for having one of the most active investments in AI-based medical technology.
“If AI companies such as Vuno and Coreline Soft work together strategically while upgrading their respective core businesses, we are confident that we will be able to expand our competitiveness in the global market,” Vuno CEO Lee Ye-Ha said in a statement.
Vatech, Medit to integrate dental AI
South Korean digital dentistry companies Vatech and Medit have partnered with United States-based Pearl for dental AI integration.
Pearl’s AI, which can automatically identify dental pathologies, will be integrated into Vatech’s diagnostic software and upcoming integrated viewer software and Medit’s centralised digital workflow platform.
Indian e-pharmacy scores $44M Series C funding
Truemeds, a digital pharmacy and telehealth platform in India, has raised Rs 375 crore ($44 million) in a Series C funding round led by Accel India and participated by WestBridge and Info Edge.
The company raised the amount from issuing shares to Accel India, which now holds a 10% stake in the company; WestBridge and Info Edge also increased their stakes to 29% and 23%, respectively.
According to a regulatory filing with the government, it plans to use the proceeds of the fundraising to pursue its growth plans.
Truemeds last raised $22 million in Series B funding in 2022.
Korea University Medical Center to test voice-based heart failure AI
Korea University Medical Center (KUMC) has signed a memorandum of understanding with startup a.cure to help further develop the latter’s AI technology.
The startup, to which KUMC transferred the rights to an AI-based technology for diagnosing pulmonary congestion in October, is currently developing a new AI for diagnosing and predicting heart failure based on voice data.
Under their MOU, both parties will cooperate to test and commercialise a.cure’s latest AI product. The startup will have access to big data and clinical research capabilities and network of KUMC. The hospital will also support a.cure in securing investments locally and abroad.
Meanwhile, a.cure will collaborate with the hospital for R&D projects with the government and for obtaining regulatory licenses.
Korea approves osteoporosis AI
Promedius, another Korean medical AI company, has recently received regulatory approval from the South Korean Ministry of Food and Drug Safety (MFDS).
It received the MFDS clearance for its osteoporosis diagnosis support AI software. The company claims that its chest X-ray-based software is less expensive than a bone density test and has lower radiation exposure risk than a volumetric bone density test.
Credit: Source link
